US SUPREME COURT TO HEAR ‘SKINNY LABEL’ PATENT FIGHT INVOLVING AMARIN
WASHINGTON, Jan 16 (Reuters) – The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma’s (AMRN.O), opens new tab cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called “skinny labels” for their products that remove specific, patented uses of a brand-name medication.
The justices took up British generic drug maker Hikma’s appeal of a lower court’s decision that let Irish-American biopharmaceutical company Amarin proceed with a lawsuit accusing Hikma of encouraging doctors to prescribe its generic version of Vascepa in ways that violated Amarin’s patent rights.
Information take from Reuters.com:
#patent #litigation #Intellectualproperty
Spanish